Antimicrobial Peptoids Show Potent Antifungal Activity against Candidozyma (Candida) auris In Vivo and Broad-Spectrum Activity In Vitro against Other Candida Species.
6 affiliations
- 1University of Louisville Center for Predictive Medicine , Louisville, Kentucky40202, United States.
- 2Department of Oral Immunology and Infectious Diseases, University of Louisville School of Dentistry, Louisville, Kentucky40202, United States.
- 3Department of Medicine, Division of Infectious Diseases and Global Medicine, University of Florida College of Medicine, Gainesville, Florida32608, United States.
- 4Department of Bioengineering, Stanford University Schools of Medicine and Engineering, Stanford, California94305, United States.
- 5Molecular Foundry, Lawrence Berkeley National Laboratory, Berkeley, California94720, United States.
- 6Department of Chemistry, New York University, New York, New York10003, United States.
Abstract
Invasive candidiasis is a serious fungal infection caused by Candida species that can enter the bloodstream and affect major organs, particularly in immunocompromised patients. Development of resistance to standard antifungal therapies, especially with C. auris, has become a major public health issue. While antimicrobial peptides such as the human cathelicidin, LL-37, could represent a possible therapeutic strategy, they are often inactivated when delivered systemically. One alternative therapeutic strategy is antimicrobial peptoids. We studied in vitro activity of three peptoid compounds, oligomers of N-substituted glycines, which mimic the activity of LL-37. Our aim was to establish these peptoid compounds as a potential treatment of invasive candidiasis and compare them to LL-37's antifungal activity. In vitro, LL-37 did not exhibit antifungal activity (MIC > 64) against all C. auris strains and three species of Candida. In contrast, three peptoids were tested against ten C. auris strains and six other Candida species and showed good activity. MICs measured as low as 4 μg/mL for TM5 against C. auris strain 381. Mechanistic studies using TEM and fluorescent confocal microscopy of peptoids against C. auris clinical isolates showed membrane disruption and consolidation of organelles. Peptoids TM4 and TM5 showed strong synergistic effects with fluconazole and caspofungin, and amphotericin B. Serial daily passage of TM4 and TM5 at sub-MIC concentrations showed no resistance developing for up to 3 weeks. Fungicidal kinetics revealed complete killing of fungal colonies after around 1 h. A systemic candidiasis mouse model treated subcutaneously with TM5 3 h after C. auris infection resulted in clearing of infection, indicated by colony forming units (cfu) per gram of kidney, at 24 h with the 5 mg/kg dose. This demonstrates that antimicrobial peptoids are active systemically and have potential to be an antifungal treatment for candidemia, particularly as an alternative therapy for resistant strains.
Related
- Antifungal activity of the nucleoside mimetic 5-fluorouridine against Candidozyma auris and Candida species
- Nanoformulated silymarin enhances antifungal activity against resistant Candida albicans by reducing ergosterol and binding to cell envelope targets
- Design, synthesis, and antifungal activity of (phenylethynyl) phenoxymethyl-1,3-dioxolane triazoles as novel CYP51 inhibitors
- Spectrum-dependent dysbiosis and recovery patterns of the gut microbiota following antimicrobial exposure
- The antibacterial and antifungal activity of honey and propolis from the Australian stingless bee Tetragonula carbonaria
BibTeX
@article{ryan2026antimicrobial,
title = {{Antimicrobial Peptoids Show Potent Antifungal Activity against Candidozyma (Candida) auris In Vivo and Broad-Spectrum Activity In Vitro against Other Candida Species.}},
author = {Lisa K Ryan and Isabella M Griffiths and Uyen Emily Do and Denny Gao and Erika L Figgins and Kristian Sørensen and Jennifer S Lin and Natalia Molchanova and Kent Kirshenbaum and Annelise E Barron and Gill Diamond},
journal = {ACS infectious diseases},
year = {2026},
month = oct,
doi = {10.1021/acsinfecdis.6c00525},
url = {https://europepmc.org/article/MED/42917104},
note = {CC BY},
}
RIS
TY - JOUR
TI - Antimicrobial Peptoids Show Potent Antifungal Activity against Candidozyma (Candida) auris In Vivo and Broad-Spectrum Activity In Vitro against Other Candida Species.
AU - Lisa K Ryan
AU - Isabella M Griffiths
AU - Uyen Emily Do
AU - Denny Gao
AU - Erika L Figgins
AU - Kristian Sørensen
AU - Jennifer S Lin
AU - Natalia Molchanova
AU - Kent Kirshenbaum
AU - Annelise E Barron
AU - Gill Diamond
PY - 2026
DA - 2026/10/01
JO - ACS infectious diseases
DO - 10.1021/acsinfecdis.6c00525
UR - https://europepmc.org/article/MED/42917104
AB - Invasive candidiasis is a serious fungal infection caused by Candida species that can enter the bloodstream and affect major organs, particularly in immunocompromised patients. Development of resistance to standard antifungal therapies, especially with C. auris, has become a major public health issue. While antimicrobial peptides such as the human cathelicidin, LL-37, could represent a possible therapeutic strategy, they are often inactivated when delivered systemically. One alternative therapeutic strategy is antimicrobial peptoids. We studied in vitro activity of three peptoid compounds, oligomers of N-substituted glycines, which mimic the activity of LL-37. Our aim was to establish these peptoid compounds as a potential treatment of invasive candidiasis and compare them to LL-37's antifungal activity. In vitro, LL-37 did not exhibit antifungal activity (MIC > 64) against all C. auris strains and three species of Candida. In contrast, three peptoids were tested against ten C. auris strains and six other Candida species and showed good activity. MICs measured as low as 4 μg/mL for TM5 against C. auris strain 381. Mechanistic studies using TEM and fluorescent confocal microscopy of peptoids against C. auris clinical isolates showed membrane disruption and consolidation of organelles. Peptoids TM4 and TM5 showed strong synergistic effects with fluconazole and caspofungin, and amphotericin B. Serial daily passage of TM4 and TM5 at sub-MIC concentrations showed no resistance developing for up to 3 weeks. Fungicidal kinetics revealed complete killing of fungal colonies after around 1 h. A systemic candidiasis mouse model treated subcutaneously with TM5 3 h after C. auris infection resulted in clearing of infection, indicated by colony forming units (cfu) per gram of kidney, at 24 h with the 5 mg/kg dose. This demonstrates that antimicrobial peptoids are active systemically and have potential to be an antifungal treatment for candidemia, particularly as an alternative therapy for resistant strains.
SN - 2373-8227
ER -